FDA Grants Full Approval to ONTAK (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
[ 2008/10/16 | Eisai Co., Ltd. | Pharmaceuticals | Tokyo | TSE1(PRIME) ]

The Company's Official Page
http://www.eisai.co.jp/enews/enews200852.html
Back To Previous Page
Dear User,
JPubb program could not collect the texts of this press-release from the official page, which perhaps mainly comprises tables, charts or images. Please refer to the official page indicated above. -- by JPubb

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

more
    この内容でのリリース掲載はまだ無いか、集計されておりません。

more

Most Popular: Pharmaceuticals

1. EISAI RECIEVES APPROVAL TO MARKET BOTULI...
Eisai Co., Ltd. 2011/01/21
2. U.S. SUBSIDIARY H3 BIOMEDICINE INC. UNDE...
Eisai Co., Ltd. 2011/01/28
3. KAKEN PHARMACEUTICAL Start Operations of...
Kaken Pharmaceutical Co.,Ltd. 2002/03/26
4. Regarding the Statement in Pfizer's...
Eisai Co., Ltd. 2009/05/09
5. Presentation of Fiscal 2009 First Quarte...
Taisho Pharmaceutical Holdings Co., Ltd. 2009/08/06

Latest News: Eisai Co., Ltd.


more

Most Popular: Eisai Co., Ltd.

1. U.S. SUBSIDIARY H3 BIOMEDICINE INC. UNDE...
2011/01/28

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

■Home

■Terms & Conditions

■Twitter ■Facebook

■About Us